These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20486816)

  • 1. Accuracy of death certificates in COPD: analysis from the TORCH trial.
    Drummond MB; Wise RA; John M; Zvarich MT; McGarvey LP
    COPD; 2010 Jun; 7(3):179-85. PubMed ID: 20486816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TORCH (towards a revolution in COPD health) survival study protocol.
    Vestbo J;
    Eur Respir J; 2004 Aug; 24(2):206-10. PubMed ID: 15332386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of COPD therapy on patient survival: the TORCH Study (TOwards a Revolution in COPD Health)].
    Nitschmann S; Schultze-Werninghaus G
    Internist (Berl); 2007 Dec; 48(12):1450-2. PubMed ID: 17965844
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
    Welsh EJ; Cates CJ; Poole P
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD007891. PubMed ID: 23728670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
    Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in COPD patients after regular use of fluticasone propionate and salmeterol.
    Marchand E
    Eur Respir J; 2003 Mar; 21(3):559-60; author reply 560. PubMed ID: 12662020
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
    Welsh EJ; Cates CJ; Poole P
    Cochrane Database Syst Rev; 2010 May; (5):CD007891. PubMed ID: 20464758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease.
    McDonough C; Blanchard AR
    Hosp Pract (1995); 2010 Apr; 38(2):92-3. PubMed ID: 20469618
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
    Baloira Villar A; Vilariño Pombo C
    Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
    Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
    Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
    Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
    Magnussen H; Disse B; Rodriguez-Roisin R; Kirsten A; Watz H; Tetzlaff K; Towse L; Finnigan H; Dahl R; Decramer M; Chanez P; Wouters EF; Calverley PM;
    N Engl J Med; 2014 Oct; 371(14):1285-94. PubMed ID: 25196117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience.
    Celli B; Vestbo J; Jenkins CR; Jones PW; Ferguson GT; Calverley PM; Yates JC; Anderson JA; Willits LR; Wise RA;
    Am J Respir Crit Care Med; 2011 Feb; 183(3):317-22. PubMed ID: 20813884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)].
    Corhay JL; Louis R
    Rev Med Liege; 2007 Apr; 62(4):230-4. PubMed ID: 17566394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice.
    Soriano JB; Vestbo J; Pride NB; Kiri V; Maden C; Maier WC
    Eur Respir J; 2002 Oct; 20(4):819-25. PubMed ID: 12412670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.
    Anzueto A; Ferguson GT; Feldman G; Chinsky K; Seibert A; Emmett A; Knobil K; O'Dell D; Kalberg C; Crater G
    COPD; 2009 Oct; 6(5):320-9. PubMed ID: 19863361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF; Timmer W; Sagkriotis A; Viel K
    Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.